This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://www.drugs.com/mtm/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/wikipedia/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/kegg-drug/
n21http://linked.opendata.cz/ontology/sukl/drug/
n22http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00579/identifier/drugbank/

Statements

Subject Item
n2:DB00579
rdf:type
n3:Drug
n3:description
Mazindol is a tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
n3:group
approved
n3:halfLife
10-13 hours
n3:indication
Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
n3:manufacturer
n5:271B4D8B-363D-11E5-9242-09173F13E4C5 n5:271B4D8C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00579 n20:DB00579
dcterms:title
Mazindol
adms:identifier
n7:D00367 n8:PA450326 n9:DB00579 n10:50005536 n11:3880 n17:4020 n18:Mazindol n19:46509094
n3:mechanismOfAction
Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.
n3:synonym
Mazindol Mazindolum Sanorex Mazindolo
n3:toxicity
Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.
n3:foodInteraction
If product causes GI problems, it can be taken during meals. May be taken without regard to meals, but preferably 1 hour before a meal.
n3:synthesisReference
U.S. Patents 3,597,445 and 3,763,178.
foaf:page
n16:mazindol.html
n3:IUPAC-Name
n4:271B4D91-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4D97-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4D96-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4D93-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4D94-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4D95-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4D8F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4DA8-363D-11E5-9242-09173F13E4C5 n4:271B4D8D-363D-11E5-9242-09173F13E4C5 n4:271B4D90-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4D8E-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:A08AA05
n3:H-Bond-Acceptor-Count
n4:271B4D9D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4D9E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4D98-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4D99-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4D9B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4D9A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4D9C-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
22232-71-9
n3:category
n3:Bioavailability
n4:271B4DA3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4DA5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4DA6-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4DA7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4DA2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4DA1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4DA4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4D92-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4D9F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4DA0-363D-11E5-9242-09173F13E4C5